Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin CH0012032048
Ticker ROG.VX
Company ROCHE
Currency CHF
Price
Aware Investor Index (AII) 27.1850
Recommendation STRONG BUY
P/E 25.58
ROE 31.75 %
Capitalization 243,281,805,200 $
Dividend Yield 3.03 %
P/S 4.42
AII Position 76
P/E Position 372
ROE Position 90
Capitalization Position 44
Dividend Yield Position 233
Sales 53,299,000,000 CHF
10-Year Average Earnings 9,210,600,000 CHF
Shares Outstanding 860,000,000
Equity 29,007,000,000 CHF
Dividend per Share 8.3 CHF
Industry Pharmaceutical
Country Switzerland
ROCHE Investor Relations Web Site http://www.roche.com/investors.htm







Sales:

YEAR MONTH AMOUNT
2017 12 53,299,000,000.00 CHF
2016 12 50,576,000,000.00 CHF
2015 12 48,145,000,000.00 CHF
2014 12 47,462,000,000.00 CHF
2013 12 46,780,000,000.00 CHF

Earnings:

YEAR MONTH AMOUNT
2017 12 8,825,000,000.00 CHF
2016 12 9,733,000,000.00 CHF
2015 12 8,863,000,000.00 CHF
2014 12 9,332,000,000.00 CHF
2013 12 11,164,000,000.00 CHF
2012 12 9,427,000,000.00 CHF
2011 12 9,343,000,000.00 CHF
2010 12 8,666,000,000.00 CHF
2009 12 7,784,000,000.00 CHF
2008 12 8,969,000,000.00 CHF

Equity:

YEAR MONTH AMOUNT
2017 12 29,007,000,000.00 CHF
2016 12 26,402,000,000.00 CHF
2015 12 23,300,000,000.00 CHF
2014 12 21,558,000,000.00 CHF
2013 12 21,241,000,000.00 CHF
2012 12 16,728,000,000.00 CHF
2011 12 14,482,000,000.00 CHF

Shares Outstanding:

YEAR MONTH AMOUNT
2017 12 860,000,000
2016 12 860,000,000
2015 12 862,000,000
2014 12 863,000,000
2013 12 863,000,000
2012 12 848,000,000
2011 12 849,000,000

 












Bloomberg News for ROCHE:



Google News for ROCHE:

Simply Wall St - 22 Jun 2019
Investors Who Bought Roche Holding (VTX:ROG) Shares A Year ...
For example, the Roche Holding AG (VTX:ROG) share price is up 26% in the last year, clearly besting than the market return of around 7.7% ...
Forbes - 27 Jun 2019
Can Roche's #1 Therapeutic Area With $28 Billion In Revenue Grow ...
Roche Holding's (NASDAQ:RHHBY) oncology portfolio is its largest therapeutic area and it will likely remain flat with revenues of around $29 ...
Zacks.com - 1 Jul 2019
Roche's Tecentriq Gets CHMP Recommendation for Breast Cancer
Roche (RHHBY - Free Report) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use ...
Wall Street Journal - 28 Apr 2019
Cancer-Drug Giant Roche Loses Edge as Rivals Grow
Many pharmaceutical companies expect cancer treatments to drive growth in the coming years. One notable exception: the world's largest ...
Bloomberg - 30 Jan 2019
Biogen Slips as Roche Spikes Alzheimer's Trials on Weak Data
Shares of Biogen Inc. came under pressure in trading before the U.S. market opened Wednesday after peer Roche Holding AG halted a pair of ...
Forbes - 4 Jun 2019
What Is Roche Holding's Fair Price Estimate Based On Expected ...
Roche Holding's (NASDAQ:RHHBY) stock price has gained 7% year-to-date, higher than a little over a 1% gain for the Dow Jones U.S. ...
Simply Wall St - 25 May 2019
What Should We Expect From Roche Holding AG's (VTX:ROG ...
The most recent earnings announcement Roche Holding AG's (VTX:ROG) released in December 2018 confirmed that the business ...
Yahoo Finance - 11 Jun 2019
Roche's Polivy Gets FDA Nod, Gazyva Meets Goals in Phase II
Roche Holdings AG RHHBY announced that the FDA has granted accelerated approval to lymphoma drug, Polivy (polatuzumab vedotin-piiq).
TheStreet.com - 10 Jun 2019
Spark Therapeutics' Shares Fall on Roche Acquisition Delay
Shares of gene-therapy company Spark Therapeutics (ONCE - Get Report) fell more than 8% Monday after the company said its pending $4.3 ...
Yahoo Finance - 17 Jun 2019
Japan becomes the first country to approve Roche's personalised ...
First tumour-agnostic medicine approved in Japan for adult and paediatric patients with NTRK fusion-positive advanced recurrent solid tumours ...


Back